NEW YORK, Dec. 13, 2011 /PRNewswire/ -- TheraBiogen, Inc. (OTC BB: TRAB), a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches, announced today that the Company's Thera Max™ Cold and Flu product will be prominently displayed on a billboard ad in Times Square at 42nd Street between 7th and 8th Avenues as part of the Company's ongoing product marketing program.
The Thera Max™ ad will run from December 15, 2011 through January 15, 2012 and will be seen by millions of people traveling through Times Square this holiday season.
Kelly Hickel, CEO of TheraBiogen, commented, "Our Times Square billboard provides significant exposure for the Thera Max™ brand through New Year's Eve and into 2012 as we continue to seek timely marketing opportunities to benefit our customers and ultimately our shareholders."
Thera Max™ Cold and Flu is an all-natural, non-zinc, non-addictive, over-the-counter cold flu relief agent. Over 50 million Americans contract the flu each year and consumer demand for a homeopathic, non-zinc remedy is a 2.5 billion dollar market.
Thera Max™ is available for purchase in over twelve thousand locations including Rite-Aid, Food Lion, Hannaford Supermarkets, Discount Drug Marts, Big Y Supermarkets and other major retailers. For more information on Thera Max™ visit our website at www.theramaxrelief.com, our Facebook page at facebook.com/theramaxnasalspray or follow us on Twitter at http://twitter.com/TheraMaxRelief.
About TheraBiogen, Inc.TheraBiogen is a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches. The products are made from natural, homeopathic ingredients and contain no zinc, which has been identified as potentially causing nasal problems in other similar products on the market. For further information please visit www.theramaxrelief.com.
Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company's most recently filed form 10-K and Form 10-Q reports. TheraBiogen, Inc. assumes no obligation to update the statements contained in this release except as required by applicable securities laws disclosure rules.
Company Contact:Public Relations Contact:Investor Contact:TheraBiogen, Inc.
Boutcher & BoutcherKelly T. Hickel, CEO
Megale Public Relations
|SOURCE TheraBiogen, Inc.|
Copyright©2010 PR Newswire.
All rights reserved